Co-creation

A published algorithm earns citations.

A certified one can save lives.

You have a model that works on your own patients. We turn it into a certified application and put it in front of every hospital running the Intellicens Data Platform, with the revenue coming back to your institution.

↓

The issue

The bottleneck is not the science

2

%

of clinical AI models developed for the ICU reach the bedside. Of 1,263 studies, 25 progressed to clinical integration.

Berkhout et al., JAMA Netw Open 2025;8(7):e2522866

A model becomes a device the moment it informs care, and a device needs a quality management system, risk management, a technical file, a clinical evaluation, cybersecurity documentation, verification and validation across every software release, penetration testing, a notified body and post-market surveillance for as long as it is in use.

That is building a software company, not a research project. Hospitals are built to deliver care. We are built for the rest of it.

↓

What your institution gets

Capitalize the IP and clinical knowledge of your team, without building a software company

Your people stay on the clinical work

No software team to hire, no quality system to stand up, no notified body to court. Your researchers keep doing research while the engineering and the regulatory file are handled next to them.

Valorization without a spin-out

Ownership is agreed before development starts. The clinical insight stays with your institution and its inventors, and your teams keep publishing on the validation work throughout.

Revenue every time it deploys

A share of recurring revenue each time your tool is activated at another hospital on the network. Your own department is the first site to benefit from it.

↓

Become part of an eco-system

The standard for ICU AI is being set right now

In five years there will be a handful of platforms that clinical AI runs on, the way there are a handful of EMRs today. The units that put their models on those platforms early are the ones whose work becomes the default. The ones that wait will be licensing someone else's.

What ends up in this catalogue is decided by which centers show up first: which clinical questions get answered, which populations, which parameters. Once a question is covered, it is covered for the network.

NICU

In multicenter validation

Intellicens Neo

Late-onset sepsis early warning, flagged a median 11 hours before clinical detection.

↳

Learn more

NICU

VALIDATED

You are a nosey bastard

You actually tried to read this. That is commitment. There is nothing here yet, but you clearly want to be the first to know when there is.

NICU

VALIDATED

Still nothing here

We could have filled this with a stock photo and the word innovation. You deserve better, so it stays empty until there is something real to put in it.

NICU

IN VALIDATION

This box is doing its best

It has a border, a rounded corner and absolutely no content. Somewhere a clinician is describing the thing that goes here, and that conversation is the actual product.

NICU

IN DEVELOPMENT

Reserved for someone's good idea

Possibly yours. The apps on this platform tend to start as a question from a unit that got tired of waiting for someone else to ask it.

PICU

In development

If you read this you owe David a beer

Belgian, cold, no negotiation. He is the one who keeps insisting that every algorithm has to explain itself before it goes anywhere near a bedside.

Adult ICU

In validation

We're going to build a spaceship

Not really. We are going to build the next decision support app. But the ambition is roughly the same, and the paperwork is arguably worse.

Your model

The next application in this catalogue has not been built yet. It may already be running in your unit.

↓

Your model, next in the marketplace

Your algorithm: certified, sold and deployed

With the Intellicens Data Platform, we provide the infrastructure to validate and deploy algorithms in every unit that needs them. We handle the data, the integration and the regulatory path, so your team keeps its focus at the bedside. And when your app runs in other hospitals, your institution shares in what it earns.

01

Integrate

Integrate

Integrate

The platform was designed to take in external models. You give us a pre-processing container and a model container, we deploy them inside Intellicens and connect them to live monitor and EMR data.

02

Validate

Validate

Validate

Validate live in your own unit, then across our network, on real patients instead of a retrospective set. The platform labels your data automatically in the background, so the evidence builds itself.

03

Certify

Certify

Certify

Your model is built on documentation that already exists. If it fits the platform's intended use it joins the platform's file; otherwise it gets a file of its own on the same base. We add what is specific to it and carry it through the notified body.

04

Deploy

Deploy

Deploy

Your model goes live in your own unit first, then across the network. Each hospital enables it as a subscription and runs it on their own servers. They pay for it, and the revenue comes back to you.

↓

Built for a catalogue

A regulatory file built for a catalogue, not a single device

Most medical device software is documented for exactly one product, so a second algorithm means a second dossier and years of the same work. Ours was structured from the start for many applications. The quality system, the platform architecture, cybersecurity, the software lifecycle and the post-market processes are documented once and shared.

A model that fits the platform's intended use is added to its file; one that goes further, like Intellicens Neo, gets a file of its own on the same base. Either way, your model adds only what is specific to it.

Done once, shared by every app

ISO 13485 quality system

Platform architecture and software lifecycle

Cybersecurity and data protection

Post-market processes

Notified body relationship with BSI, MD 817890

Routes defined under EU MDR 2017/745 and the FDA 510(k) pathway

Added per model

Clinical evaluation

Risk analysis

Verification and validation

For every model we take to market, we are the legal manufacturer for as long as it runs: post-market surveillance, vigilance, updates and every release after certification. Your institution never has to be.

↓Before the first meeting

Questions your legal and IT teams will ask

Ownership is agreed before development starts, in writing. The clinical insight stays with your institution and its inventors, Innocens holds the platform and the regulatory file, and your institution shares in the revenue each time the tool is deployed at another hospital. Publication rights on the validation work stay with your team.

Models that run on what the platform already reads: time-series signals from the bedside monitors and context from the electronic medical record, for patients in intensive care. Ideally the model already holds up on your own patients, at least retrospectively. Prospective validation then runs on the platform itself: we integrate and deploy it, and you validate it live in your own unit. The platform proposes labels that your clinicians confirm while reviewing patients, and it calculates the performance metrics as the evidence accumulates. From there the same validation can be extended to other sites we work with, which is what turns it into a multicenter study.

No. The platform was designed to take in external models. You hand over a pre-processing container and a model container, we deploy them inside Intellicens and connect them to live monitor and EMR data. Nothing is ported, reimplemented or rewritten in someone else's framework.

On your own infrastructure. Intellicens is deployed on-premise or in your private cloud, patient data does not leave your perimeter, and your institution retains ownership of it in an accessible and extractable form. Access runs through your identity provider and your role model, and every view and export is logged.

Deployment and evidence. Your device runs on the same on-premise stack the platform already uses: the sensor and EMR connectors, the on-site installation and the training hospitals expect. Real-world evidence is then generated continuously from the sites where it runs, which is usually the hardest part to arrange alone.

No. A spin-out solves the manufacturer problem on paper, but it means founding a company, hiring a software team and standing up a quality management system, years before the first patient benefits. Co-creation exists so an institution can turn clinical knowledge into a certified tool without any of that. Where a spin-out is already planned, the same structure works alongside it.

Intellicens is sensor-agnostic. It connects to bedside monitors over HL7 and to the electronic medical record over FHIR, using interfaces your hospital already runs. No new hardware at the bedside, and it never alters or replaces the primary monitor.

A validated model, a clinical lead who can commit time, and a data access agreement with your ethics committee and data protection officer. From there we scope the regulatory route in the EU and the US and the integration into your own unit. If you have a clinical question rather than a model, the place to start is the platform itself: validating on live primary data in your own unit is what it exists for.